Arvinas
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Arvinas and other ETFs, options, and stocks.About ARVN
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer.
CEOJohn G. Houston
CEOJohn G. Houston
Employees430
Employees430
HeadquartersNew Haven, Connecticut
HeadquartersNew Haven, Connecticut
Founded2013
Founded2013
Employees430
Employees430
ARVN Key Statistics
Market cap579.63M
Market cap579.63M
Price-Earnings ratio-1.49
Price-Earnings ratio-1.49
Dividend yield—
Dividend yield—
Average volume1.38M
Average volume1.38M
High today$7.92
High today$7.92
Low today$7.62
Low today$7.62
Open price$7.75
Open price$7.75
Volume1.03M
Volume1.03M
52 Week high$29.61
52 Week high$29.61
52 Week low$5.90
52 Week low$5.90
Analyst ratings
58%
of 19 ratingsBuy
57.9%
Hold
42.1%
Sell
0%
People also own
Based on the portfolios of people who own ARVN. This list is generated using Robinhood data, and it’s not a recommendation.